Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:

• Age ≥ 18 years.

• Both male and female will be included.

• Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Time Frame
Start Date: 2025-11-20
Estimated Completion Date: 2026-11-28
Participants
Target number of participants: 80
Treatments
Active_comparator: Control group
control group ( levo-dopa group, n =40 ) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months.
Active_comparator: Celecoxib group
will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus celecoxib 200 mg once daily.
Sponsors
Leads: Tanta University

This content was sourced from clinicaltrials.gov